Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today

blonca9
Aug 1, 2024
1 min read

Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for neurofibromatosis Type 1 into a phase 2 study.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight